""
JAMA Dermatology Publishes Data Showing upadacitinib Achieved Superiority Versus dupilumab for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis 4 years ago
